Sector News

Activists want Spectrum to dump its CEO and find a buyer

May 13, 2015
Life sciences
Hedge fund Armistice Capital has taken a 5.4% stake in Spectrum Pharmaceuticals, agitating for sweeping changes in how the biotech does business and demanding it find a buyer on the quick.
 
Armistice, led by founder Steve Boyd, contends that Spectrum is bloated, poorly managed and in desperate need of change after years of broken promises. In a letter to Spectrum’s board, Boyd disclosed his firm’s 3.6 million-share stake and asked the company to dump its “money-losing” R&D activities and recruit a “top-tier investment bank” to find a buyer. In the meantime, CEO Rajesh Shrotriya should either resign or “adjust (his) compensation to better align with the interests of shareholders,” Boyd wrote.
 
The last straw, according to Armistice, came in February when Spectrum’s shares plunged after a federal court invalidated some patents tied to the cancer drug Fusilev, clearing the way of Novartis’ Sandoz to launch a generic. That very night, with half of Spectrum’s revenue suddenly imperiled, the company awarded $2 million in cash bonuses to its top four execs, according to Boyd, typifying the “dysfunctional culture” that has marred shareholder value.
 
To groom Spectrum for an acquisition, Boyd proposes “a combination of reducing management compensation and employee headcount, significantly curtailing research and development, eliminating excessive corporate offices, and focusing on in-licensing and co-promotion opportunities.” He mentions the research-averse Valeant Pharmaceuticals as a potential model, recommending Spectrum spin out some of its riskier pipeline assets into a standalone biotech company.
 
In making his case, Boyd lays out a long list of failings and misguided projections from Shrotriya and Spectrum’s management, including promises that Fusilev was safe through 2022 and that the bladder cancer treatment apaziquone would be submitted to the FDA in 2013. It remains unfiled.
 
“I will be the first to acknowledge that the business of forecasting is a thankless profession,” Boyd wrote. “Nonetheless, the disconnect between your statements and reality have created distrust in the investment community, employee turnover, shareholder lawsuit expense and an SEC investigation that is on-going.”
 
Spectrum’s shares rose more than 7% before the market opened on Tuesday.
 
By Damian Garde
 

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.